[go: up one dir, main page]

PE20081484A1 - Polimorfos de un antagonista del receptor mglur5 - Google Patents

Polimorfos de un antagonista del receptor mglur5

Info

Publication number
PE20081484A1
PE20081484A1 PE2007001802A PE2007001802A PE20081484A1 PE 20081484 A1 PE20081484 A1 PE 20081484A1 PE 2007001802 A PE2007001802 A PE 2007001802A PE 2007001802 A PE2007001802 A PE 2007001802A PE 20081484 A1 PE20081484 A1 PE 20081484A1
Authority
PE
Peru
Prior art keywords
mglur5 receptor
polymorphes
receptor antagonist
antagonist
neuroliogical
Prior art date
Application number
PE2007001802A
Other languages
English (en)
Inventor
Thomas P Cleary
Alexander Glomme
Olaf Grassmann
Shan-Ming Kuang
Roland Meier
Doreen Miller
Regina Moog
Franziska E Rohrer
Jason Yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39186951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081484(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20081484A1 publication Critical patent/PE20081484A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMA CRISTALINA MONO-SULFATO DE 2-CLORO-4-[1-(4-FLUOR-FENIL)-2,5-DIMETIL-1H-IMIDAZOL-4-ILETINIL]-PIRIDINA CARACTERIZADA POR LO MENOS DE 3 PICOS ELEGIDOS ENTRE LOS SIGUIENTES PICOS DE DIFRACCION DE RAYOS X OBTENIDOS CON UNA CUkALFA A 2THETA GRADOS: 9,8: 13,4; 14,2; 18,1; 18,9; 22,6; 22,9; 25,7; 27,1 Y 29,9 (+-0,2 2-THETA) Y UN ESPECTRO INFRARROJO QUE TIENE BANDAS ACUSADAS A 3068, 2730, 2618, 2236, 2213, 1628, 1587, 1569, 1518, 1384, 1374, 902, 855, 786 674 CM-1 (+-3cm-1). REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION QUE CONSISTE EN LA FORMACION DE LA SAL CON ACIDO SULFURICO EN 2-PROPANOL Y POSTERIOR PRECIPITACION ESPONTANEA. DICHO POLIMORFO ES ANTAGONISTA DEL RECEPTOR mGLUR5 UTIL EN EL TRATAMIENTO DE TRASTORNOS NEUROLIOGICOS TAL COMO ANSIEDAD, DOLOR CRONICO, PROTECCION CONTRA LESION HEPATICA, INCONTINENCIA ORINARIA, ENTRE OTROS
PE2007001802A 2006-12-21 2007-12-14 Polimorfos de un antagonista del receptor mglur5 PE20081484A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87639806P 2006-12-21 2006-12-21

Publications (1)

Publication Number Publication Date
PE20081484A1 true PE20081484A1 (es) 2008-10-18

Family

ID=39186951

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001802A PE20081484A1 (es) 2006-12-21 2007-12-14 Polimorfos de un antagonista del receptor mglur5

Country Status (32)

Country Link
US (2) US8063076B2 (es)
EP (1) EP2125779B1 (es)
JP (1) JP5405311B2 (es)
KR (1) KR101148580B1 (es)
CN (1) CN101568531B (es)
AR (1) AR064654A1 (es)
AU (1) AU2007336369B2 (es)
CA (1) CA2673444C (es)
CL (1) CL2007003695A1 (es)
CO (1) CO6210731A2 (es)
CY (1) CY1117810T1 (es)
DK (1) DK2125779T3 (es)
EC (1) ECSP099431A (es)
ES (1) ES2577391T3 (es)
HR (1) HRP20160950T1 (es)
HU (1) HUE029324T2 (es)
IL (1) IL199181A (es)
MA (1) MA31008B1 (es)
MX (1) MX2009006694A (es)
MY (1) MY148217A (es)
NO (1) NO342451B1 (es)
NZ (1) NZ577440A (es)
PE (1) PE20081484A1 (es)
PL (1) PL2125779T3 (es)
PT (1) PT2125779T (es)
RS (1) RS54853B1 (es)
RU (1) RU2460728C2 (es)
SI (1) SI2125779T1 (es)
TW (1) TWI347320B (es)
UA (1) UA96970C2 (es)
WO (1) WO2008074697A1 (es)
ZA (1) ZA200904289B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2125779B1 (en) 2006-12-21 2016-04-27 F. Hoffmann-La Roche AG Polymorphs of a mglur5 receptor antagonist
US20120039999A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
BR112013023813A2 (pt) 2011-03-18 2016-12-13 Novartis Ag combinações de ativadores do receptor acetilcolina nicotínico alfa 7 e antagonistas de mglur5 para uso em dopamina induzida por discinesia na doença de parkinson
EP2837631A1 (en) 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
GB201317022D0 (en) * 2013-09-25 2013-11-06 Addex Pharmaceuticals Sa Polymorphs
ES2916873T3 (es) 2014-01-10 2022-07-06 Birdie Biopharmaceuticals Inc Compuestos y composiciones para inmunoterapia
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
MX2022015407A (es) * 2020-06-05 2023-05-16 Noema Pharma Ag Metodos de tratamiento del complejo de esclerosis tuberosa.
CN115989024A (zh) * 2020-07-30 2023-04-18 诺埃玛制药公司 治疗三叉神经痛的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3303199A (en) 1963-07-15 1967-02-07 Geigy Chem Corp Certain imidazolone derivatives and process for making same
US3341548A (en) 1964-04-29 1967-09-12 Hoffmann La Roche Nitroimidazoles and their preparation
DE2035905A1 (de) 1970-07-20 1972-02-03 Chemische Fabrik Stockhausen & Cie.,4150Krefeld Imidazolverbindungen und deren Herstellungsverfahren
CA1174673A (en) 1981-02-27 1984-09-18 Walter Hunkeler Imidazodiazepines
US4508560A (en) 1981-11-11 1985-04-02 Ciba Geigy Corporation Certain pyridylacetylene compounds, compositions containing same and herbicidal methods of use
US4711962A (en) 1984-10-18 1987-12-08 Stauffer Chemical Company Process for selective preparation of ratios of isomers formed on N-substitution of asymmetric imidazoles
DE69025473T2 (de) 1989-06-30 1996-10-17 Du Pont Substituierte imidazole und ihre verwendung als hemmmstoff fur angiotensin ii
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
ATE262331T1 (de) 1997-08-14 2004-04-15 Hoffmann La Roche Heterocyclische vinylether zur behandlung neurologischer krankheiten
EP1214303A1 (en) 1999-08-31 2002-06-19 Merck & Co., Inc. Heterocyclic compounds and methods of use thereof
ES2346513T3 (es) 2000-07-24 2010-10-18 Krenitsky Pharmaceuticals, Inc. 5-alquinil pirimidinas sustituidas que tienen actividad neurotrofica.
CN1257894C (zh) 2000-12-04 2006-05-31 弗·哈夫曼-拉罗切有限公司 作为谷氨酸受体拮抗剂的苯基乙烯基或苯基乙炔基衍生物
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
CA2470612A1 (en) 2001-12-19 2003-07-03 Merck & Co., Inc. Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7091222B2 (en) 2003-07-03 2006-08-15 Hoffmann-La Roche Inc. Imidazole derivatives
US7452909B2 (en) 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
EP1756086B1 (en) * 2004-06-01 2008-06-04 F.Hoffmann-La Roche Ag Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
EP2125779B1 (en) 2006-12-21 2016-04-27 F. Hoffmann-La Roche AG Polymorphs of a mglur5 receptor antagonist

Also Published As

Publication number Publication date
RU2009123135A (ru) 2011-01-27
TWI347320B (en) 2011-08-21
CA2673444C (en) 2015-01-20
PT2125779T (pt) 2016-07-19
JP2010513378A (ja) 2010-04-30
MA31008B1 (fr) 2009-12-01
CN101568531A (zh) 2009-10-28
ES2577391T3 (es) 2016-07-14
UA96970C2 (en) 2011-12-26
CA2673444A1 (en) 2008-06-26
IL199181A (en) 2016-02-29
HRP20160950T1 (hr) 2016-10-07
ZA200904289B (en) 2010-04-28
SI2125779T1 (sl) 2016-07-29
MY148217A (en) 2013-03-29
ECSP099431A (es) 2009-07-31
CY1117810T1 (el) 2017-05-17
HUE029324T2 (en) 2017-02-28
US20080312288A1 (en) 2008-12-18
AR064654A1 (es) 2009-04-15
DK2125779T3 (en) 2016-07-04
AU2007336369A1 (en) 2008-06-26
RU2460728C2 (ru) 2012-09-10
US20120035222A1 (en) 2012-02-09
MX2009006694A (es) 2009-06-30
BRPI0720954A2 (pt) 2014-03-18
CL2007003695A1 (es) 2008-07-04
RS54853B1 (sr) 2016-10-31
EP2125779B1 (en) 2016-04-27
TW200833679A (en) 2008-08-16
US8329912B2 (en) 2012-12-11
AU2007336369B2 (en) 2013-01-17
US8063076B2 (en) 2011-11-22
KR101148580B1 (ko) 2012-05-24
KR20090081026A (ko) 2009-07-27
NO20092357L (no) 2009-07-15
EP2125779A1 (en) 2009-12-02
CO6210731A2 (es) 2010-10-20
NO342451B1 (no) 2018-05-22
WO2008074697A1 (en) 2008-06-26
NZ577440A (en) 2011-12-22
PL2125779T3 (pl) 2016-11-30
JP5405311B2 (ja) 2014-02-05
CN101568531B (zh) 2013-11-13

Similar Documents

Publication Publication Date Title
PE20081484A1 (es) Polimorfos de un antagonista del receptor mglur5
GT201200164A (es) "nuevos compuestos de espiropiperidina"
WO2010132999A8 (en) Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
SI2150530T1 (sl) Substituirani sulfonamidni derivati
MX2009011749A (es) Compuestos triciclicos como inhibidores de metaloproteinasa matricial.
RU2017117413A (ru) Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
MX2012015096A (es) Compuestos heterociclicos fusionados como moduladores del canal ion.
PH12016501204B1 (en) Syk inhibitors
ZA201100526B (en) Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
NZ600430A (en) Spiro-oxindole mdm2 antagonists
MX2011010347A (es) Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos.
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
PE20070845A1 (es) Derivados de pirazolo[1,5-alfa]pirimidin utiles como receptores antagonistas del factor de liberacion de corticotropina (crf)
UY29339A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
PE20061018A1 (es) Sales de adicion de acido de piperidin-4-ilamina del acido 4-(2,6-dicloro-benzoil-amino)-1h-pirazol-3-carboxilico como inhibidores de quinasa
CL2009001747A1 (es) Composicion farmaceutica que comprende 0,05-0,3% de peroxido de hidrogeno, 0,001-0,03% de eugenol, 0,001-0,01% de alcanfor, 0,001-0,5% de una sal de zinc u otros metales pesados definidos, 1-1,2% de fluoruro de sodio, 2-7% de xilitol y excipientes; metodo de preparacion; uso para prevenir y/o tratar enfermedades orales.
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
MX2009000169A (es) Derivados de purinona como agonistas de hm74a.
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
AR076300A1 (es) Derivados de pirimidin imidazoles sustituidos, inhibidores de gsk3, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del alzheimer, enfermedades neurodegenerativas agudas, diabetes y otras enfermedades.
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
WO2009096701A3 (en) Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
MX2011011058A (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
MA32290B1 (fr) Nouvelle classe de spiro pipéridines pour le traitement de maladies neurodégénératives

Legal Events

Date Code Title Description
FC Refusal